D101 100 Pill - orange oval
Generic Name: tovorafenib
Pill with imprint D101 100 is Orange, Oval and has been identified as Ojemda 100 mg. It is supplied by Day One Biopharmaceuticals, Inc.
Ojemda is used in the treatment of Low-Grade Glioma and belongs to the drug class multikinase inhibitors. Ojemda 100 mg is not a controlled substance under the Controlled Substances Act (CSA).
Images for D101 100
Ojemda
- Generic Name
- tovorafenib
- Imprint
- D101 100
- Strength
- 100 mg
- Color
- Orange
- Shape
- Oval (film-coated)
- Availability
- Prescription only
- Drug Class
- Multikinase inhibitors
- CSA Schedule
- Not a controlled drug
- Labeler / Supplier
- Day One Biopharmaceuticals, Inc.
- National Drug Code (NDC)
- 82950-0001
See also:
Tafinlar
Tafinlar is a prescription medicine used to treat BRAF mutated melanoma, non-small cell lung ...
Mekinist
Mekinist is used to treat melanoma, non-small cell lung cancer, thyroid cancer, solid tumors, and ...
Botox
Botox is used for cosmetic purposes and to treat overactive bladder symptoms, urinary incontinence ...
Alecensa
Alecensa (alectinib) is an oral kinase inhibitor that may be used to treat certain types of ...
Alunbrig
Alunbrig (brigatinib) is used to treat anaplastic lymphoma kinase-positive (ALK+) metastatic ...
Augtyro
Augtyro (repotrectinib) is a next-generation TKI (Tyrosine Kinase Inhibitor) cancer medicine used ...
Ayvakit
Ayvakit (avapritinib) is a prescription medicine used for the treatment of gastrointestinal stromal ...
Balversa
Balversa (erdafitinib) is an oral kinase inhibitor that may be used to treat adults with locally ...
Braftovi
Braftovi is a targeted cancer treatment used in combination with Mektovi, mFOLFOX6, or Erbitux, to ...
More about Ojemda (tovorafenib)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: multikinase inhibitors
- En español
Patient resources
Professional resources
Related treatment guides
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.